Aducanumab is a medication used in the management and treatment of Alzheimer disease. It is an amyloid beta-directed monoclonal antibody. This activity describes the indications, action, and contraindications for aducanumab as a possible agent in the management of Alzheimer disease. Aducanumab indications in Alzheimer disease are specific to subjects with mild cognitive impairment or mild dementia stage of the progressive neurodegenerative ailment. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients with Alzheimer disease.

**Objectives:**
- Discuss the mechanism of action of aducanumab.
- Describe the indicated use for aducanumab.
- Explain the possible side effects of aducanumab.
- Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when dosing and monitoring aducanumab treatment for Alzheimer disease.